After a drug survives Phase I safety testing, it moves to Phase II, the phase where the most important clinical question begins to be answered: does this drug actually work?
From Safety to Effectiveness
Phase II trials are the first time a drug is systematically tested for effectiveness in people who have the condition it is designed to treat. They begin to evaluate: – Whether the drug shows meaningful biological activity – What dose appears optimal for effectiveness – What the side effect profile looks like in patients with the disease – Whether there are signals of benefit worth pursuing in a larger trial
Size and Structure
Phase II trials typically enroll 100 to 300 participants. They are usually randomized, some receive the experimental drug, others receive placebo or comparator treatment, and often double-blind.
Many promising drugs fail at Phase II because they do not demonstrate sufficient effectiveness signals to justify the massive investment of Phase III.
What Participants Experience
- Multiple clinic visits over several months to a year
- Regular assessments of disease severity using validated scoring tools
- Blood and urine testing
- Patient-reported outcome questionnaires
- Study medication or placebo per the protocol
All visits, testing, and study medications are provided at no cost.
For Patients With Difficult-to-Treat Conditions
For patients whose conditions are not well controlled by existing treatments, Phase II participation may represent an opportunity to access a treatment that could become a future standard of care.
Browse active studies at NuLine or apply to see if you qualify.